Rephonic
Artwork for Journal of Clinical Oncology

Journal of Clinical Oncology (JCO) Podcast

American Society of Clinical Oncology (ASCO)
Breast Cancer
Non-Small Cell Lung Cancer
Overall Survival
Clinical Trials
Oncology
Immunotherapy
Pembrolizumab
Chemotherapy
Just ASK Initiative
ASCO
Endometrial Cancer
Progression-Free Survival
Bevacizumab
Muscle Invasive Bladder Cancer
Gastric Cancer
Prostate Cancer
Smoking Cessation
Cancer Survivorship
Rituximab
Smoking Assessment

The Journal of Clinical Oncology Podcast presents analyses and discussions centered on the latest findings published in ASCO's flagship Journal of Clinical Oncology. Host Dr. Davide Soldato facilitates interviews and scholarly discourse on the most impactful published findings. The Journal of Clinical Oncology Podcast is the trusted resource that empowers you to integrate cutting-edge evidence int... more

PublishesTwice monthlyEpisodes462Founded15 years ago
Number of ListenersCategories
MedicineHealth & Fitness

Listen to this Podcast

Artwork for Journal of Clinical Oncology

Latest Episodes

Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India" and the innovative breath-based ca... more

YouTube

JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update ... more

YouTube

JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearr... more

YouTube

JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pool... more

YouTube

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

ASCO Daily News
ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)
Two Onc Docs
Two Onc DocsSam and Karine
ASCO Guidelines
ASCO GuidelinesAmerican Society of Clinical Oncology (ASCO)
NEJM This Week
NEJM This WeekNEJM Group
ASCO Education
ASCO EducationAmerican Society of Clinical Oncology (ASCO)

Recent Guests

Kathy Miller
JCO Senior Deputy Editor
Journal of Clinical Oncology
Episode: JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
Dr. Andrea Necchi
JCO associate editor
Journal of Clinical Oncology
Episode: JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
Dr. Glenwood Goss
JCO author; Professor of Medicine; past chair of the Canadian Thoracic Oncology Site Committee
University of Ottawa; Ottawa Hospital Cancer Center
Episode: Adjuvant Durvalumab and the Future of Early-Stage NSCLC
John Wingard
JCO author, Professor Emeritus
University of Florida
Episode: Infections in Two Diet Strategies in HSCT and Leukemia Patients
John Gore
JCO author, urologist at Fred Hutch Cancer Center and professor of urology at University of Washington School of Medicine
Fred Hutch Cancer Center; University of Washington
Episode: The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC
Professor Andrea Necchi
Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy
University San Raffaele
Episode: Milan Consensus Endpoints for Bladder Preservation in MIBC
Professor Ashish Kamat
Professor of Urology, Oncology, and Cancer Research at University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Episode: Milan Consensus Endpoints for Bladder Preservation in MIBC
Dr. Rusha Bhandari
Pediatric hematologist oncologist and assistant professor in the Department of Pediatrics and Population Science at City Hope
City Hope
Episode: Health Outcomes in Older Childhood Cancer Survivors
Professor Sundar Jagannath
Professor of Medicine at Icahn School of Medicine at Mount Sinai and network director for the Center of Excellence for Multiple Myeloma.
Icahn School of Medicine at Mount Sinai
Episode: Long-Term Remission After Cilta-cel in Patients With RRMM

Host

Dr. Davide Soldato
Host of JCO-related podcasts; oncologist with hospital affiliation in Genoa, Italy

Reviews

4.1 out of 5 stars from 87 ratings
  • Good Information, but

    The information provided is important, but the presenters are stilted.

    Apple Podcasts
    4
    Jtn2
    United States10 years ago
  • I really want to like this podcast, but...

    unfortunately, although the content is excellent, the delivery is awful. Most of the time the presenters just read the text of the podcast - very fast, in a monotonous voice. While as a written piece it could perhaps work, it doesn't work as an audio. I end up pausing and rewinding, and eventually giving up on learning and remembering. An audio lecture needs to be delivered at a slower pace, with fewer lists and numbers...

    Apple Podcasts
    2
    Zoirusha
    United States13 years ago
  • Nice

    Good platform

    Apple Podcasts
    5
    Gazelle73
    United States15 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

High-quality content with valuable clinical insights; pacing could improve.
Overall, brings expert trial interpretation to clinicians seeking evidence-based practice.
Delivery can feel stiff or overly lecture-like for some listeners.
Guest variety is strong and topics stay relevant to oncology practice.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Q: What are the implications for practice and next steps?
A larger phase III trial is needed to confirm the findings and potentially change practice; if positive, it could influence neoadjuvant and adjuvant treatment paradigms and extend neoantigen vaccine strategies to broader cancer settings.
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Q: Can you tell us a little bit more about what some of the key results are?
The study showed a meaningful five-year relapse-free and dysmetastasis-free survival advantage with the vaccine plus Pembrolizumab, including significant hazard ratios, while overall survival trended positively but was not conclusive due to the small sample size.
JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
Q: Could you walk us through the key results and how they might impact clinical practice?
The trial did not meet its primary endpoint, but the broader post-hoc response rate approached 30%, and the 24-month event-free survival was about 71%, which is meaningful in a high-risk group. Many patients chose to avoid cystectomy after strong responses, and biomarker analyses hinted that certain molecular subtypes and low top-1 expression may predict better outcomes, suggesting a potential role for bladder preservation and personalized approaches while acknowledging the need for validation in larger randomized trials.
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
Q: Can you comment on the major strengths and the limitations of this study?
The major strength is the large combined dataset of about 1,500 patients, with randomization to low-dose tamoxifen or no therapy, while the limitation is that it did not directly compare low-dose to full-dose tamoxifen or include a rheumatase inhibitor arm in postmenopausal women.
Adjuvant Durvalumab and the Future of Early-Stage NSCLC
Q: what is your take on MRD analyses and their potential to guide future treatment strategies in this setting?
MRD positivity appears prognostic and may identify a high-risk subset that could benefit from altered or intensified adjuvant therapy, but the current MRD findings are exploratory and require prospective validation in randomized trials before altering standard practice.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Journal of Clinical Oncology

What is Journal of Clinical Oncology about and what kind of topics does it cover?

This show centers on in-depth discussions of articles from a premier oncology journal, with a primary focus on trial design, biomarker insights, and evolving treatment paradigms across solid tumors and hematologic cancers. Episodes routinely dissect clinical trial results, translational data, and practical implications for patient management, often highlighting how biomarkers, imaging, sequencing of therapies, and real-world constraints shape outcomes. A notable strength is bringing together active trial authors and clinicians to translate complex findings into real-world practice, while ongoing coverage reveals when promising strategies do not translate into long-term benefits and why that gap matters for clinicians and researchers alike.

Where can I find podcast stats for Journal of Clinical Oncology?

Rephonic provides a wide range of podcast stats for Journal of Clinical Oncology. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Journal of Clinical Oncology and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Journal of Clinical Oncology get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Journal of Clinical Oncology, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Journal of Clinical Oncology?

Rephonic provides comprehensive predictive audience data for Journal of Clinical Oncology, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Journal of Clinical Oncology have?

To see how many followers or subscribers Journal of Clinical Oncology has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Journal of Clinical Oncology?

These podcasts share a similar audience with Journal of Clinical Oncology:

1. ASCO Daily News
2. Two Onc Docs
3. ASCO Guidelines
4. NEJM This Week
5. ASCO Education

How many episodes of Journal of Clinical Oncology are there?

Journal of Clinical Oncology launched 15 years ago and published 462 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Journal of Clinical Oncology?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Journal of Clinical Oncology?

Rephonic pulls ratings and reviews for Journal of Clinical Oncology from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Journal of Clinical Oncology?

Rephonic provides full transcripts for episodes of Journal of Clinical Oncology. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Journal of Clinical Oncology?

Recent guests on Journal of Clinical Oncology include:

1. Kathy Miller
2. Dr. Andrea Necchi
3. Dr. Glenwood Goss
4. John Wingard
5. John Gore
6. Professor Andrea Necchi
7. Professor Ashish Kamat
8. Dr. Rusha Bhandari

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days